IP Library › Granted Patent US 7,709,458
Granted Patent B2
US 7,709,458 · App. 11/079,779 · Granted May 4, 2010

Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis

Assignee: David K. R. Karaolis
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,458
App. No.
11/079,779
Granted
May 4, 2010
Kind
B2
Abstract

Cyclic di-GMP or cyclic dinucleotides thereof can be used to inhibit cancer cell proliferation or to increase cancer cell apoptosis in vitro as well as in vivo in a patient.

Claims (12)

1. A method for reducing cancer cell proliferation or increasing cancer cell apoptosis in a patient in need thereof, comprising administering to said patient an effective amount of cyclic di-GMP or a cyclic dinucleotide, as the sole active ingredient, to reduce cancer cell proliferation or increase cancer cell apoptosis in the patient.

2. The method of claim 1 , wherein an effective amount of cyclic di-GMP is administered to the patient in need thereof.

3. The method of claim 1 , wherein an effective amount of a cyclic dinucleotide is administered to the patient in need thereof.

4. The method of claim 3 , wherein said cyclic dinucleotide is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)

5. The method of claim 1 , wherein the cancer cells in which proliferation is reduce or apoptosis is increased are colon cancer cells.

6. The method of claim 1 , wherein the cancer cells in which proliferation is reduced or apoptosis is increased are selected from the group consisting of cancer cells originating from the pancreas, breast, lung, brain, prostate, squamous cells, lymphoid cells, and leukocytes.

7. A method for reducing cancer cell proliferation or increasing cancer cell apoptosis in a patient in need thereof, comprising administering to said patient an effective amount of cyclic di-GMP or a cyclic dinucleotide, in combination with an anti-cancer agent, to reduce cancer cell proliferation or increase cancer cell apoptosis in the patient.

8. The method of claim 7 , wherein an effective amount of cyclic di-GMP is administered to the patient in need thereof.

9. The method of claim 7 , wherein an effective amount of a cyclic dinucleotide is administered to the patient in need thereof.

10. The method of claim 9 , wherein said cyclic dinucleotide is selected from the group consisting of cyclic dinucleotide compounds (I)-(XX)

11. The method of claim 7 , wherein the cancer cells in which proliferation is reduced or apoptosis is increased are colon cancer cells.

12. The method of claim 7 , wherein the cancer cells in which proliferation is reduced or apoptosis is increased are selected from the group consisting of cancer cells originating from the pancreas, breast, lung, brain, prostate, squamous cells, lymphoid cells, and leukocytes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2012
From: KARAOLIS, DAVID
To: KARAGEN PHARMACEUTICALS
Reel/Frame 028045/0533 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2005
From: RAUFMAN, JEAN-PIERRE
To: KARAOLIS, DAVID K. R.
Reel/Frame 016414/0346 →
Continuity (3)
Provisional Application 6055272100 · Mar 15, 2004
Provisional Application 6056369200 · Apr 20, 2004
Related Publication 20050203051A1 · Sep 15, 2005